In phase I/II trial of 28 patients with R/R FLT3-ITD mutated AML with prior FLT3 inhibitor treatment, the triplet quizartinib, decitabine, and venetoclax showed promising interim results, with a composite CR (cCR) rate of 82% [73]. Here, FLT3 is linked to acute myeloid leukemia.